What is Bexson Biomedical?
Bexson Biomedical, Inc. is a research-stage company focused on developing a novel ketamine-based combination product platform. The company aims to address a wide spectrum of pain management and mental health disorders. Established in 2017 and headquartered in Santa Barbara, California, Bexson Biomedical is positioning itself at the intersection of pharmaceutical innovation and critical unmet medical needs.
How much funding has Bexson Biomedical raised?
Bexson Biomedical has raised a total of $4.8M across 1 funding round:
Series A
$4.8M
Series A (2021): $4.8M with participation from Noetic Psychedelic Fund
Key Investors in Bexson Biomedical
Noetic Psychedelic Fund
Noetic Psychedelic Fund is an investment firm that appears to specialize in companies operating within the psychedelic therapeutics and mental health sectors, aligning with Bexson Biomedical's focus.
What's next for Bexson Biomedical?
The recent major strategic investment signifies a pivotal moment for Bexson Biomedical, likely enabling the company to accelerate its research and development pipeline. This enterprise-level funding suggests a focus on scaling operations, advancing clinical trials, and potentially expanding its therapeutic indications. The company's trajectory indicates a strong push towards validating its platform and preparing for broader market entry.
See full Bexson Biomedical company page
